Enzon Pharmaceuticals, Inc. (ENZN)
USD 0.1
(0.0%)
USD 0.1
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.04 Million USD | -1.16% |
| 2022 | -1.03 Million USD | -120.04% |
| 2021 | -469 Thousand USD | 64.06% |
| 2020 | -1.3 Million USD | -34.12% |
| 2019 | -973 Thousand USD | -116.62% |
| 2018 | 5.85 Million USD | -16.45% |
| 2017 | 7 Million USD | 5.48% |
| 2016 | 6.64 Million USD | -38.48% |
| 2015 | 10.8 Million USD | -62.49% |
| 2014 | 28.79 Million USD | 58.54% |
| 2013 | 18.15 Million USD | 557.87% |
| 2012 | -3.96 Million USD | 75.9% |
| 2011 | -16.45 Million USD | -2761.74% |
| 2010 | -575 Thousand USD | -160.34% |
| 2009 | 953 Thousand USD | -68.78% |
| 2008 | 3.05 Million USD | -96.63% |
| 2007 | 90.49 Million USD | 761.85% |
| 2006 | 10.5 Million USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 7.04 Million USD | -76.45% |
| 2003 | 29.89 Million USD | -13.63% |
| 2002 | 34.61 Million USD | 1103.38% |
| 2001 | 2.87 Million USD | 131.23% |
| 2000 | -9.2 Million USD | -50.97% |
| 1999 | -6.1 Million USD | -52.5% |
| 1998 | -4 Million USD | 23.08% |
| 1997 | -5.2 Million USD | 24.64% |
| 1996 | -6.9 Million USD | 5.48% |
| 1995 | -7.3 Million USD | 56.55% |
| 1994 | -16.8 Million USD | 33.6% |
| 1993 | -25.3 Million USD | 16.5% |
| 1992 | -30.3 Million USD | -119.57% |
| 1991 | -13.8 Million USD | -25.45% |
| 1990 | -11 Million USD | -41.03% |
| 1989 | -7.8 Million USD | -59.18% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -325 Thousand USD | 0.31% |
| 2024 Q1 | -326 Thousand USD | -50.93% |
| 2024 Q3 | 205 Thousand USD | -8.0% |
| 2023 Q2 | -318 Thousand USD | -11.58% |
| 2023 Q1 | -285 Thousand USD | -35.07% |
| 2023 Q4 | -216 Thousand USD | 4.0% |
| 2023 Q3 | -225 Thousand USD | 29.25% |
| 2023 FY | -1.04 Million USD | -1.16% |
| 2022 Q2 | -303 Thousand USD | -2.02% |
| 2022 Q1 | -297 Thousand USD | -28.57% |
| 2022 FY | -1.03 Million USD | -120.04% |
| 2022 Q4 | -211 Thousand USD | 4.52% |
| 2022 Q3 | -221 Thousand USD | 27.06% |
| 2021 Q2 | -21 Thousand USD | -290.91% |
| 2021 Q1 | 11 Thousand USD | 102.61% |
| 2021 FY | -469 Thousand USD | 64.06% |
| 2021 Q3 | -228 Thousand USD | -985.71% |
| 2021 Q4 | -231 Thousand USD | -1.32% |
| 2020 Q3 | -407 Thousand USD | -72.46% |
| 2020 Q4 | -422 Thousand USD | -3.69% |
| 2020 FY | -1.3 Million USD | -34.12% |
| 2020 Q1 | -240 Thousand USD | 6.98% |
| 2020 Q2 | -236 Thousand USD | 1.67% |
| 2019 Q4 | -258 Thousand USD | 20.62% |
| 2019 Q3 | -325 Thousand USD | -1447.62% |
| 2019 FY | -973 Thousand USD | -116.62% |
| 2019 Q2 | -21 Thousand USD | 94.31% |
| 2019 Q1 | -369 Thousand USD | -105.36% |
| 2018 FY | 5.85 Million USD | -16.45% |
| 2018 Q1 | -311 Thousand USD | 7.72% |
| 2018 Q3 | -519 Thousand USD | -151.94% |
| 2018 Q2 | -206 Thousand USD | 33.76% |
| 2018 Q4 | 6.88 Million USD | 1426.78% |
| 2017 Q2 | 6.43 Million USD | 490.1% |
| 2017 Q3 | -184 Thousand USD | -102.86% |
| 2017 Q4 | -337 Thousand USD | -83.15% |
| 2017 FY | 7 Million USD | 5.48% |
| 2017 Q1 | 1.09 Million USD | 67.08% |
| 2016 Q4 | 653 Thousand USD | -59.44% |
| 2016 FY | 6.64 Million USD | -38.48% |
| 2016 Q2 | 1.83 Million USD | -27.86% |
| 2016 Q3 | 1.61 Million USD | -12.31% |
| 2016 Q1 | 2.54 Million USD | 7.29% |
| 2015 Q4 | 2.37 Million USD | 356.16% |
| 2015 Q2 | 4.67 Million USD | -0.04% |
| 2015 FY | 10.8 Million USD | -62.49% |
| 2015 Q3 | -926 Thousand USD | -119.8% |
| 2015 Q1 | 4.67 Million USD | -19.34% |
| 2014 Q4 | 5.8 Million USD | -23.61% |
| 2014 Q1 | 8.46 Million USD | 69.78% |
| 2014 Q2 | 6.93 Million USD | -18.15% |
| 2014 Q3 | 7.59 Million USD | 9.57% |
| 2014 FY | 28.79 Million USD | 58.54% |
| 2013 Q1 | 3.15 Million USD | 138.26% |
| 2013 Q4 | 4.98 Million USD | -2.64% |
| 2013 Q3 | 5.12 Million USD | 4.53% |
| 2013 Q2 | 4.9 Million USD | 55.56% |
| 2013 FY | 18.15 Million USD | 557.87% |
| 2012 FY | -3.96 Million USD | 75.9% |
| 2012 Q4 | -8.23 Million USD | -302.73% |
| 2012 Q3 | 4.06 Million USD | 1578.1% |
| 2012 Q2 | 242 Thousand USD | 772.22% |
| 2012 Q1 | -36 Thousand USD | 99.1% |
| 2011 Q4 | -4.01 Million USD | 48.28% |
| 2011 Q3 | -7.76 Million USD | -29.36% |
| 2011 Q2 | -6 Million USD | -553.25% |
| 2011 Q1 | 1.32 Million USD | 112.53% |
| 2011 FY | -16.45 Million USD | -2761.74% |
| 2010 Q1 | 22.45 Million USD | 5472.73% |
| 2010 FY | -575 Thousand USD | -160.34% |
| 2010 Q2 | -5.07 Million USD | -122.6% |
| 2010 Q3 | -7.39 Million USD | -45.67% |
| 2010 Q4 | -10.56 Million USD | -42.86% |
| 2009 Q4 | -418 Thousand USD | -154.36% |
| 2009 Q3 | 769 Thousand USD | 122.31% |
| 2009 Q2 | -3.44 Million USD | -194.08% |
| 2009 Q1 | 3.66 Million USD | 7865.22% |
| 2009 FY | 953 Thousand USD | -68.78% |
| 2008 Q4 | 46 Thousand USD | 866.67% |
| 2008 Q3 | -6000.00 USD | -101.59% |
| 2008 Q1 | 2.63 Million USD | 202.99% |
| 2008 Q2 | 377 Thousand USD | -85.7% |
| 2008 FY | 3.05 Million USD | -96.63% |
| 2007 Q4 | 870 Thousand USD | -99.04% |
| 2007 Q2 | -985 Thousand USD | -515.63% |
| 2007 FY | 90.49 Million USD | 761.85% |
| 2007 Q3 | 90.61 Million USD | 9299.7% |
| 2007 Q1 | -160 Thousand USD | 98.63% |
| 2006 FY | 10.5 Million USD | 0.0% |
| 2006 Q4 | -11.63 Million USD | -1938.39% |
| 2006 Q3 | 633 Thousand USD | -93.89% |
| 2006 Q2 | 10.35 Million USD | -7.14% |
| 2006 Q1 | 11.15 Million USD | 0.0% |
| 2005 FY | - USD | -100.0% |
| 2005 Q4 | - USD | -100.0% |
| 2005 Q3 | 1.71 Million USD | -27.38% |
| 2005 Q2 | 2.36 Million USD | 1156.7% |
| 2005 Q1 | -224 Thousand USD | -105.0% |
| 2004 Q1 | -6.7 Million USD | -187.71% |
| 2004 FY | 7.04 Million USD | -76.45% |
| 2004 Q3 | 3.95 Million USD | 257.25% |
| 2004 Q4 | 4.48 Million USD | 13.47% |
| 2004 Q2 | -2.51 Million USD | 62.56% |
| 2003 Q3 | 8.61 Million USD | -51.12% |
| 2003 Q2 | 17.62 Million USD | 45.5% |
| 2003 Q1 | 12.11 Million USD | 184.19% |
| 2003 Q4 | 7.64 Million USD | -11.2% |
| 2003 FY | 29.89 Million USD | -13.63% |
| 2002 Q1 | 9.74 Million USD | 12.89% |
| 2002 Q2 | 13.09 Million USD | 34.41% |
| 2002 Q4 | -14.38 Million USD | -198.89% |
| 2002 Q3 | 14.54 Million USD | 11.06% |
| 2002 FY | 34.61 Million USD | 1103.38% |
| 2001 Q4 | 8.63 Million USD | 175.5% |
| 2001 FY | 2.87 Million USD | 131.23% |
| 2001 Q1 | 2.61 Million USD | 1983.92% |
| 2001 Q2 | 1.67 Million USD | -36.18% |
| 2001 Q3 | 3.13 Million USD | 87.54% |
| 2000 Q4 | 125.63 Thousand USD | 108.17% |
| 2000 Q1 | -2.16 Million USD | -20.45% |
| 2000 Q2 | -3.02 Million USD | -39.39% |
| 2000 Q3 | -1.53 Million USD | 49.09% |
| 2000 FY | -9.2 Million USD | -50.97% |
| 1999 Q2 | -1.8 Million USD | -5.88% |
| 1999 FY | -6.1 Million USD | -52.5% |
| 1999 Q3 | -2.2 Million USD | -22.22% |
| 1999 Q4 | -1.8 Million USD | 18.18% |
| 1999 Q1 | -1.7 Million USD | -41.67% |
| 1998 Q3 | -1.4 Million USD | 41.67% |
| 1998 FY | -4 Million USD | 23.08% |
| 1998 Q2 | -2.4 Million USD | -33.33% |
| 1998 Q4 | -1.2 Million USD | 14.29% |
| 1998 Q1 | -1.8 Million USD | -350.0% |
| 1997 Q1 | -2 Million USD | -122.22% |
| 1997 Q2 | -1.3 Million USD | 35.0% |
| 1997 FY | -5.2 Million USD | 24.64% |
| 1997 Q4 | -400 Thousand USD | -166.67% |
| 1997 Q3 | 600 Thousand USD | 146.15% |
| 1996 Q2 | -1 Million USD | 54.55% |
| 1996 Q1 | -2.2 Million USD | -37.5% |
| 1996 Q4 | -900 Thousand USD | 0.0% |
| 1996 FY | -6.9 Million USD | 5.48% |
| 1996 Q3 | -900 Thousand USD | 10.0% |
| 1995 FY | -7.3 Million USD | 56.55% |
| 1995 Q3 | -2.1 Million USD | -320.0% |
| 1995 Q2 | -500 Thousand USD | 37.5% |
| 1995 Q1 | -800 Thousand USD | 77.78% |
| 1995 Q4 | -1.6 Million USD | 23.81% |
| 1994 Q1 | 600 Thousand USD | 110.0% |
| 1994 Q2 | -5.3 Million USD | -983.33% |
| 1994 Q3 | -2.3 Million USD | 56.6% |
| 1994 Q4 | -3.6 Million USD | -56.52% |
| 1994 FY | -16.8 Million USD | 33.6% |
| 1993 Q4 | -6 Million USD | 0.0% |
| 1993 Q1 | -7.2 Million USD | -14.29% |
| 1993 Q2 | -6.3 Million USD | 12.5% |
| 1993 FY | -25.3 Million USD | 16.5% |
| 1993 Q3 | -6 Million USD | 4.76% |
| 1992 Q4 | -6.3 Million USD | -16.67% |
| 1992 Q1 | -6 Million USD | 52.76% |
| 1992 FY | -30.3 Million USD | -119.57% |
| 1992 Q2 | -8.1 Million USD | -35.0% |
| 1992 Q3 | -5.4 Million USD | 33.33% |
| 1991 Q3 | -3.3 Million USD | 15.38% |
| 1991 FY | -13.8 Million USD | -25.45% |
| 1991 Q1 | -3.7 Million USD | -562.5% |
| 1991 Q2 | -3.9 Million USD | -5.41% |
| 1991 Q4 | -12.7 Million USD | -284.85% |
| 1990 Q2 | -12.9 Million USD | -2250.0% |
| 1990 Q3 | 100 Thousand USD | 100.78% |
| 1990 Q4 | 800 Thousand USD | 700.0% |
| 1990 Q1 | 600 Thousand USD | 0.0% |
| 1990 FY | -11 Million USD | -41.03% |
| 1989 Q3 | 600 Thousand USD | 105.83% |
| 1989 Q4 | 600 Thousand USD | 0.0% |
| 1989 Q2 | -10.3 Million USD | -2160.0% |
| 1989 Q1 | 500 Thousand USD | -37.5% |
| 1989 FY | -7.8 Million USD | -59.18% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 21.823% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 79.304% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 94.15% |
| Nascent Biotech, Inc. | -2.22 Million USD | 53.181% |
| Rebus Holdings, Inc. | -664 Thousand USD | -57.229% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.275% |
| Qrons Inc. | -643.67 Thousand USD | -62.193% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -167.988% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 98.119% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -151.276% |
| Skye Bioscience, Inc. | -13.67 Million USD | 92.364% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 98.546% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 121.242% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -298.89% |
| SQZ Biotechnologies Company | -75.82 Million USD | 98.623% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 63.375% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 32.033% |
| Mesoblast Limited | -84.14 Million USD | 98.759% |
| Marizyme, Inc. | -34.08 Million USD | 96.937% |
| Genus plc | 6.4 Million USD | 116.313% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 110.716% |
| Pharming Group N.V. | -4.87 Million USD | 78.605% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 47.445% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -12.092% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 87.497% |
| ContraFect Corporation | -56.88 Million USD | 98.165% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 77.079% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 25.534% |
| IMV Inc. | -38.67 Million USD | 97.3% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 62.048% |
| MultiCell Technologies, Inc. | -722.81 USD | -144336.297% |
| ONE Bio Corp. | 13.68 Million USD | 107.631% |
| Accustem Sciences Inc. | -3.74 Million USD | 72.133% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 98.23% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -116.121% |
| Q BioMed Inc. | -3.44 Million USD | 69.701% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 129.492% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 60.267% |
| Biomind Labs Inc. | -1 Million USD | -3.407% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 98.101% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 64.016% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 84.296% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 44.003% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -3385.577% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 93.421% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 45.98% |
| GB Sciences, Inc. | -1.42 Million USD | 26.505% |
| Alpha Cognition Inc. | -9.7 Million USD | 89.243% |
| HST Global, Inc. | -140.9 Thousand USD | -640.914% |
| CSL Limited | 3.7 Billion USD | 100.028% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 7.192% |
| Halberd Corporation | -75.05 Thousand USD | -1291.073% |
| Enzolytics Inc. | -2.14 Million USD | 51.415% |
| Agentix Corp. | -1.37 Million USD | 23.893% |
| Resverlogix Corp. | -12.74 Million USD | 91.811% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 67.048% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.754% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 64.24% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 33.897% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 69.339% |
| AVAX Technologies, Inc. | 6.69 Million USD | 115.599% |
| Zenith Capital Corp. | -8.94 Million USD | 88.326% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.749% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -5892.767% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 57.48% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -508.712% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 47.924% |
| Kadimastem Ltd | -3.04 Million USD | 65.661% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -6.092% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 16.879% |
| BioStem Technologies, Inc. | -7.77 Million USD | 86.579% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -475.254% |
| LadRx Corporation | -3.82 Million USD | 72.696% |
| Cell Source, Inc. | -4.32 Million USD | 75.863% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -51.976% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -51.976% |
| NovAccess Global Inc. | -2.46 Million USD | 57.677% |
| Affymax, Inc. | -15.04 Million USD | 93.061% |
| Itoco Inc. | -919.14 Thousand USD | -13.584% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 75.368% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 6.702% |
| Mobile Lads Corp. | -554.55 Thousand USD | -88.261% |
| CytoDyn Inc. | -18.05 Million USD | 94.219% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -4047.795% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -374.377% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -84.869% |
| SYBLEU INC | -149.18 Thousand USD | -599.826% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 42.521% |
| International Stem Cell Corporation | -663 Thousand USD | -57.466% |
| Bioxytran, Inc. | -3.82 Million USD | 72.671% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1883.283% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -5032.743% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 97.121% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 35.476% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -41.88% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 66.442% |
| Neutra Corp. | -229.48 Thousand USD | -354.93% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 94.048% |
| PureTech Health plc | -146.19 Million USD | 99.286% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 95.142% |
| IXICO plc | -1.43 Million USD | 27.349% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 89.0% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.143% |
| CSL Limited | 3.81 Billion USD | 100.027% |
| Cellectis S.A. | -108.85 Million USD | 99.041% |